This is Archived Content

This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). Find the latest information on substance use, health, and NIDA research at

Cite this article

NIDA. (2009, October 1). Teleconference Discussion of Results from Cocaine Vaccine Study . Retrieved from

press ctrl+c to copy

October 01, 2009

Doctors Volkow and Kosten will discuss the findings of a study in the October issue of Archives of General Psychiatry evaluating the safety and efficacy of a vaccine to treat cocaine addiction. Currently there is no FDA-approved medication for treating cocaine addiction.

WHAT: Teleconference on newly released results from a National Institute on Drug Abuse sponsored trial of an anti-cocaine treatment vaccine

WHO: NIDA Director Dr. Nora Volkow and lead investigator, Dr. Thomas Kosten, Baylor College of Medicine

WHEN: Monday, October 5th - 4:00 to 5:00pm Eastern Daylight Time. EST

WHERE: Operator assisted live dial-in event at: 888-567-1602 (U.S. and Canada) or (201) 604-5049 (international callers).

The Substance Abuse and Mental Health Services Administration (SAMHSA) is a public health agency also within the Department of Health and Human Services. The agency is responsible for improving the accountability, capacity and effectiveness of the nation's substance abuse prevention, addictions treatment, and mental health services delivery system.

The White House Office of National Drug Control Policy (ONDCP), a component of the Executive Office of the President, was established by the Anti-Drug Abuse Act of 1988. The principal purpose of ONDCP is to establish policies, priorities, and objectives for the Nation's drug control program. The goals of the program are to reduce illicit drug use, manufacturing, and trafficking, drug-related crime and violence, and drug-related health consequences.